Clinical recommendations for cardiology and comorbid diseases. Coronary heart disease

REFERENCES

· Diagnostics and treatment of chronic ischemic heart disease. Russian recommendations. Moscow, 2013. 69 p. (in Russian)

· Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations. VI revision. Ateroskleroz i dislipidemii [Atherosclerosis and dyslipidemia]. 2017; 28 (3): 5–22. (in Russian)

· Cardiovascular prevention 2017. Russian national guidelines. Rossiyskiy kardiologicheskiy zurnal [Russian journal of cardiology]. 2018; (6): 7–122. (in Russian)

· 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease. Eur Heart J. 2013; 34: 2949–3003.

· 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. Circulation. 2014; 130: 1749–67.

· 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Circulation. 2016; 134: e196–e197.

· 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37: 2999–3058.

· 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018; 39: 1131–43.

· 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019; 2: 87–165.

· 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA.

· NLA/PCNA Guideline on the Management of Blood Cholesterol. J. Am. Coll. Cardiol. 2019; 73 (24): 3168–209.

· 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019.

· ACCF/AHA 2013 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Stable Ischemic Heart Disease. J Am Coll Cardiol. 2014; 63: 380–406.

· ACP/ACCF/AHA/AATS/PCNA/STA. Diagnosis of Stable Ischemic Heart Disease. Ann Intern Med. 2012;157: 729–34.

· ACP/ACCF/AHA/AATS/PCNA/STA. Management of Stable Ischemic Heart Disease. Ann Intern Med. 2012; 157: 735–43.

· AHA. Secondary Prevention after Coronary Artery Bypass Graft Surgery. Circulation. 2015; 131: 927–64.

· Brilakis E., Mashayekhi K., Tsuchikane E., et al. Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. A Global Expert Consensus Document. Circulation. 2019; 5: 420–33.

· AHA. Recommendations for Clinical Exercise Laboratories. A Scientific Statement from the American Heart Association. Circulation. 2009; 119: 3144–61.

· ESC. Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J. 2014; 35: 1510–14.

· Exercise Standards for Testing and Training: A Scientifi c Statement from the AHA. Circulation. 2013; 128: 873–934.

· NICE. Management of Stable Angina. 2011. 34 p.

· Screening for Coronary Heart Disease with Electrocardiography: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012; 157: 512–18.

· Urban P., Mehran R., Colleran R., et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019; 31: 2632–53.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)